Arcadia Biosciences (RKDA) Q4 2025 earnings summary

Executive summary

• Zola coconut water brand revenues grew 17% year-over-year in 2025, outpacing the category.

• Full-year total revenues declined 4% to $4.86 million due to the absence of GLA oil sales.

• SG&A expenses were reduced by 27% year-over-year, contributing to improved net loss.

• The proposed business combination with Roosevelt Resources was terminated at year-end 2025.

• $2.1 million in gross proceeds were raised through the exercise of preferred investment options.

Financial highlights

• Fourth quarter revenues fell 26% year-over-year to $901,000, mainly due to lower Zola sales and no GLA oil sales.

• Full-year net loss attributable to common stockholders improved to $2.3 million from $7.1 million in 2024.

• Fourth quarter net loss attributable to common stockholders was $1.4 million, down from $4.1 million in Q4 2024.

• Loss from continuing operations improved 31% year-over-year to $2.5 million.

Outlook and guidance

• Proceeds from investment options and other assets will be used to grow the Zola brand and evaluate strategic alternatives.

• The company will require additional funding in the near future to continue operations and planned activities.